References
- Adinolfi LE. Prevalence and incidence of cryoglobulins in chronic hepatitis C patients. Am J Gastroenterol 2003;98:2568–9.
- Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007;39:2–17.
- Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J 2002;19:756–64.
- Schwarz MI, Zamora MR, Hodges TN, Chan ED, Bowler RP, Tuder RM. Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective tissue disease. Chest 1998;113:1609–15.
- Prasad M, Buller GK, Mena CI, Sofair AN. Clinical problem-solving. Sum of the parts. N Engl J Med 2006;355:2468–73.
- Gomez-Tello V, Onoro-Canaveral JJ, de la Casa Monje RM, Gomez-Casero RB, Moreno Hurtrez JL, Garcia-Montes M, Diffuse recidivant alveolar hemorrhage in a patient with hepatitis C virus-related mixed cryoglobulinemia. Intensive Care Med 1999;25:319–22.
- Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20:23–8.
- KDIGO Clinical Practice Guidelines for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Guideline 5: diagnosis and management of kidney diseases associated with HCV infection. Kidney Int 2008;73(Suppl 109):S69–77.
- Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67:283–7.
- Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008;67:1431–6.